论文部分内容阅读
目的:观察参麦注射液联合多西他赛、奈达铂治疗非小细胞肺癌(NSCLC)的临床效果。方法:68例NSCLC患者随机分为2组,各34例。对照组采取多西塔塞+奈尔铂化疗治疗,观察组在对照组治疗基础上给予参麦注射液静脉滴注治疗。比较2组临床效果及不良反应发生情况。结果:证候总显效率观察组82.35%,对照组55.88%,2组比较,差异有统计学意义(P<0.05)。观察组恶心呕吐发生率、白细胞下降发生率、血小板减少、谷丙转氨酶、肾功能受损及腹泻,与对照组比较,差异均有统计学意义(P<0.05),观察组发生率显著低于对照组。结论:参麦注射液联合多西他赛、奈达铂治疗方案治疗NSCLC效果显著,并可降低化疗毒副作用。
Objective: To observe the clinical effect of Shenmai injection combined with docetaxel and nedaplatin in the treatment of non-small cell lung cancer (NSCLC). Methods: Sixty-eight NSCLC patients were randomly divided into two groups (34 in each). The control group was treated with docetaxel + nel platinum, and the observation group was treated with intravenous infusion of Shenmai injection on the basis of the control group. The clinical effects and adverse reactions in two groups were compared. Results: The overall syndrome marked efficiency of 82.35% in the observation group, 55.88% in the control group, the difference between the two groups was statistically significant (P <0.05). The incidence of nausea and vomiting, the incidence of leukopenia, thrombocytopenia, alanine aminotransferase, renal dysfunction and diarrhea in the observation group were significantly different from those in the control group (P <0.05). The incidence of the observation group was significantly lower than that of the control group Control group. Conclusion: Shenmai injection combined with docetaxel, nedaplatin treatment of NSCLC significant effect, and can reduce the side effects of chemotherapy.